Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the sale of four ...

In response to market changes and users' needs, JETOUR will launch the hybrid T2 i-DM based on T2 model. It inherits T2's exceptional product capabilities and upgrades the powertrain system ...

In response to market changes and users' needs, JETOUR will launch the hybrid T2 i-DM based on T2 model. It inherits T2's exceptional product capabilities and upgrades the powertrain system, offering ...

LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the ...

LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the ...

T2 Biosystems, Inc. announced the sale of four T2Dx® Instruments to its European distributor, marking significant commercial expansion and enhancing its international market presence. The sale ...

Selling a second T2Dx Instrument to a major reference hospital to expand “same store” sales; Selling the first T2Dx Instrument to a hospital in a country for initial market penetration; and Selling ...

(MENAFN- GlobeNewsWire - Nasdaq) Multiple instrument sale demonstrates growing market penetration of T2 Biosystems' sepsis tests LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc.

T2 Biosystems (TTOO) announced the sale of four T2Dx Instruments to its European distributor that represents multiple EU counties, demonstrating commercial expansion and increased international ...